Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

ST-Segment Elevation Infarction After TAVR: Problems in Every Aspect

For interventional cardiologists, treating an ST-segment elevation infarction in a patient with transcatheter aortic valve replacement (TAVR) is challenging in many ways. Longer door-to-balloon times and higher rates of primary angioplasty failure than in the general population are translated into very high short- and mid-term mortality.

Infarto con supradesnivel del ST post TAVI: problemas en todos los sentidos

This multicenter study, recently published in JACC, included 118 patients admitted with ST-segment elevation infarction at a mean of 225 days (range: 9 to 680 days) after valvular implantation.

The characteristics of post-TAVR infarction patients who underwent primary angioplasty were compared with 439 patients without prior TAVR who underwent primary angioplasty in the same time period.

The mean door-to-balloon time was higher for TAVR patients (40 minutes vs. 30 minutes [p = 0.003]). Procedure time, fluoroscopy time, radiation dose, and contrast volume were significantly higher for the TAVR population (p < 0.01 for all).

The primary angioplasty failure rate was 4x higher in those with implanted valves (16.5% vs. 3.9%; p < 0.001), including 5 patients whose culprit artery could not be catheterized.

In-hospital mortality was 25.4%, while mid-term mortality (7 months) was as high as 42.4%.

Renal impairment and Killip class >II were 3x more frequent in patients with previous TAVR (hazard ratio [HR]: 3.02; p = 0.004; and HR: 2.74; p = 0.004, respectively).


Read also: New Cardiac Failure Diagnoses after COVID-19 Infection.


All these more frequent events in the TAVR population explain the higher short- and mid-term mortality.

Conclusion

ST-segment elevation infarctions in patients with prior TAVR are associated with much higher short- and mid-term mortality. Longer door-to-balloon times and higher primary angioplasty failure rates are due, partly, to difficulties accessing coronary arteries.

Original Title: ST-Segment Elevation Myocardial Infarction Following Transcatheter Aortic Valve Replacement.

Reference: Laurent Faroux et al. J Am Coll Cardiol. 2021 May 4;77(17):2187-2199. doi: 10.1016/j.jacc.2021.03.014.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...